EcoDrugPlus

Porcupine O-Acyltransferase

Ensembl ID : ENSOTSG00005006665
Gene Symbol: PORCN
1 Cross references
186 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSOTSG00005023937
Gene Symbol: PORCNL
1 Cross references
191 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSOTSG00005039798
Gene Symbol: PORCNL
1 Cross references
191 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSOTSG00005026138
Gene Symbol: KCNN4
1 Cross references
178 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSOTSG00005030052
Gene Symbol: KCNN4
1 Cross references
178 Possible Orthologues:

Potassium Channel Subfamily K Member 3-Like

Ensembl ID : ENSOTSG00005029714
Gene Symbol: LOC112251696
3 Cross references
196 Possible Orthologues:

Potassium Channel Subfamily K Member 3-Like

Ensembl ID : ENSOTSG00005044407
Gene Symbol: LOC112217434
3 Cross references
196 Possible Orthologues:

Potassium Channel Subfamily K Member 9-Like

Ensembl ID : ENSOTSG00005036518
Gene Symbol: LOC112265901
3 Cross references
212 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSOTSG00005028765
Gene Symbol: KCNK2B
1 Cross references
213 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSOTSG00005044350
Gene Symbol: KCNK9
1 Cross references
212 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSOTSG00005017441
Gene Symbol: KCNJ11
1 Cross references
182 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSOTSG00005034022
Gene Symbol: KCNJ11
1 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).